GSK's Arexvy RSV Vaccine Recommended For Expanded Use In Adults 18+ By EMA Committee

GSK's RSV vaccine Arexvy won a positive opinion from the EMA's CHMP to expand its indication to all adults aged 18+, with a final European Commission decision due in February 2026; Arexvy is already approved in Europe for adults 60+ and some 50–59-year-olds at increased risk. If authorized, the label expansion would significantly broaden the vaccine's addressable market against a disease that affects an estimated 64 million people globally each year, strengthening GSK's commercial opportunity as it pursues similar regulatory expansions in the US and Japan, though ultimate impact depends on final approvals and uptake.

Analysis

The EMA's CHMP has issued a positive opinion recommending expansion of GSK's adjuvanted recombinant RSV vaccine Arexvy to all adults aged 18+, with a final European Commission decision expected in February 2026. Arexvy is already the first RSV vaccine approved in Europe to prevent lower respiratory tract disease (LRTD) in adults 60+ and in 50–59 year-olds at increased risk, so an approval would materially broaden the on-label population.

If authorized for 18+, the addressable population expands meaningfully against a disease that affects an estimated 64 million people globally each year, strengthening GSK's commercial opportunity; GSK is simultaneously pursuing similar regulatory expansions in the US and Japan. Market signals attached to the report are moderately positive (sentiment_score 0.5, GSK per-ticker 0.6) but the market_impact_score of 0.38 implies limited near-term pricing reaction until the formal EC decision.

Primary upside depends on regulatory approval, payer coverage and real-world uptake; downside stems from the binary regulatory outcome in Feb 2026 and subsequent reimbursement or demand shortfalls. Investors should watch the formal EC decision, subsequent national reimbursement decisions, and the timelines for US and Japan filings as the main catalysts and risks to the revenue outlook.

Key Decisions for Investors

• Consider a modest overweight in GSK to capture upside potential ahead of the February 2026 EC decision, but size the position conservatively given the binary regulatory risk
• Use hedges or options to limit downside during the approval window and re-evaluate after the EC decision and any national reimbursement announcements
• Monitor regulatory timelines in the US and Japan and early real-world uptake and coverage signals post-approval as triggers to increase conviction or trim exposure